WallStSmart

Definitive Healthcare Corp (DH)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 43601% more annual revenue ($99.33B vs $227.31M). JNJ leads profitability with a 16.2% profit margin vs -69.2%. JNJ earns a higher WallStSmart Score of 54/100 (C-).

DH

Hold

37

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: -1.24

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHUndervalued (+74.6%)

Margin of Safety

+74.6%

Fair Value

$6.66

Current Price

$1.26

$5.40 discount

UndervaluedFair: $6.66Overvalued

Intrinsic value data unavailable for JNJ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DH2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

DH4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$140.38M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-116.5%2/10

ROE of -116.5% — below average capital efficiency

Revenue GrowthGrowth
-9.0%2/10

Revenue declined 9.0%

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DH

The strongest argument for DH centers on Price/Book, Debt/Equity.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bear Case : DH

The primary concerns for DH are EPS Growth, Market Cap, Return on Equity.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.

Key Dynamics to Monitor

DH profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.

DH carries more volatility with a beta of 1.36 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 37/100), backed by strong 16.2% margins. DH offers better value entry with a 74.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Definitive Healthcare Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.

Visit Website →

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?